GO:0045348 positive regulation of MHC class II biosynthetic process: Immune Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045348 describes any process that activates or increases the frequency, rate or extent of MHC class II biosynthesis, a central step in adaptive immunity.
• MHC class II molecules present exogenous antigens to CD4+ T cells, and their abundance is tightly controlled at the level of biosynthesis and trafficking.
• Positive regulation of MHC class II biosynthesis is critical for anti-tumor immunity, as intratumoral CD4+ T cells require MHC class II for cytotoxicity.
• Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity in BRAF-mutant anaplastic thyroid cancers.
• MHC class II-restricted antigen presentation prevents dysfunction of cytotoxic T cells in brain tumors.
• Dysregulated MHC class II biosynthesis contributes to autoimmunity, fibrosis, and neurodegeneration, making it a therapeutic target [2,5,7].
Description
The Gene Ontology term GO:0045348, positive regulation of MHC class II biosynthetic process, encompasses any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of MHC class II molecules. MHC class II proteins are heterodimeric cell-surface glycoproteins that present processed exogenous antigens to CD4+ T helper cells, thereby initiating and shaping adaptive immune responses. Because the level of MHC class II expression determines the efficiency of antigen presentation, its biosynthesis is subject to multiple layers of positive regulation, including transcriptional activation, post-translational stabilization, and endosomal routing [6,8]. Researchers study GO:0045348 to understand how immune surveillance is maintained and how its dysregulation contributes to cancer, autoimmunity, and chronic inflammatory diseases [1,3,5]. For example, intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer, and this function depends on MHC class II expression. In BRAF-mutant anaplastic thyroid cancers, loss of tumor cell MHC class II drives MAPK inhibitor insensitivity, highlighting the clinical relevance of MHC class II biosynthetic regulation. Similarly, MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells in brain tumors. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0045348, covering its definition, biological significance, key genes, disease associations, and experimental methods for studying it.
positive regulation of MHC class II biosynthetic process At A Glance
| GO ID | GO:0045348 |
|---|---|
| GO term | positive regulation of MHC class II biosynthetic process |
| Ontology | biological_process |
| Synonym | activation of MHC class II biosynthetic process; positive regulation of major histocompatibility complex class II biosynthesis; upregulation of MHC class II biosynthetic process |
| Major function | Increases the production of MHC class II molecules, enhancing antigen presentation to CD4+ T cells |
| Related processes | Antigen processing and presentation, endosomal trafficking, immune response |
| Cellular location | Endoplasmic reticulum, endosomes, lysosomes, plasma membrane |
| Key regulators | CIITA, RFX complex, NF-Y, CREB, and post-translational modifiers such as March-I |
What Is GO:0045348?
GO:0045348 is defined as any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of MHC class II. In other words, it covers all positive regulatory events—transcriptional, post-transcriptional, translational, and post-translational—that elevate the production of MHC class II molecules. This term is a child of positive regulation of MHC class II biosynthetic process and is distinct from negative regulation or from the biosynthetic process itself.
Why Is positive regulation of MHC class II biosynthetic process Important in Cell Biology?
Positive regulation of MHC class II biosynthesis is essential for effective adaptive immunity because the density of MHC class II molecules on antigen-presenting cells determines the strength and quality of CD4+ T cell activation. Dysregulation of this process is implicated in cancer immune evasion, autoimmune diseases, and chronic inflammatory conditions, making it a critical area of biomedical research [1,3,5].
• Controls the efficiency of exogenous antigen presentation to CD4+ T cells.
• Required for anti-tumor immunity mediated by intratumoral CD4+ T cells in bladder cancer.
• Loss of MHC class II biosynthesis drives MAPK inhibitor insensitivity in BRAF-mutant anaplastic thyroid cancers.
• MHC class II-restricted antigen presentation prevents cytotoxic T cell dysfunction in brain tumors.
• MHC class II in renal tubules plays an essential role in renal fibrosis.
• Disease-specific oligodendrocyte lineage cells in multiple sclerosis show altered MHC class II expression.
• Regulation of MHC class II and CD86 by March-I influences immunity and disease.
• Suppression of JAK/STAT pathway inhibits neuroinflammation in Parkinson's disease models, linking MHC class II regulation to neurodegeneration.
What Happens During positive regulation of MHC class II biosynthetic process?
Transcriptional activation of MHC class II genes
In simple terms: The cell turns on the genes that make MHC class II proteins.
The MHC class II genes (HLA-DR, HLA-DP, HLA-DQ in humans) are primarily regulated at the transcriptional level by the master transactivator CIITA (class II transactivator). Positive regulation involves the recruitment of CIITA to MHC class II promoters, where it interacts with the RFX complex, NF-Y, and CREB to form an enhanceosome that drives robust transcription. This step is the first and rate-limiting step in MHC class II biosynthesis.
Post-transcriptional and translational control
In simple terms: After the genes are turned on, the cell fine-tunes how much protein is made.
Following transcription, MHC class II mRNA stability and translation can be positively regulated by cytokines such as IFN-gamma, which also induces CIITA expression. This ensures that MHC class II protein levels match the demands of antigen presentation.
Assembly and folding in the endoplasmic reticulum
In simple terms: The protein subunits are put together and folded inside the cell.
The MHC class II alpha and beta chains are synthesized in the endoplasmic reticulum (ER), where they assemble into heterodimers and associate with the invariant chain (Ii, CD74). This complex is essential for proper folding and for preventing premature peptide binding.
Endosomal trafficking and peptide loading
In simple terms: The assembled MHC class II molecules travel to endosomes to pick up antigen fragments.
The MHC class II-invariant chain complexes are transported from the ER to endosomal compartments, where the invariant chain is progressively degraded by cathepsins, leaving a CLIP fragment in the peptide-binding groove. HLA-DM then facilitates the exchange of CLIP for high-affinity antigenic peptides, a key step in MHC class II biosynthesis and maturation.
Post-translational stabilization and surface expression
In simple terms: The final MHC class II molecules are stabilized and sent to the cell surface.
Ubiquitination by March-I (MARCH1) regulates the turnover of MHC class II molecules, and positive regulation can involve inhibition of March-I or enhancement of recycling to the plasma membrane. This step controls the steady-state level of surface MHC class II and thus the capacity to present antigens.
Key Genes Involved in GO:0045348 positive regulation of MHC class II biosynthetic process
The following genes and proteins are central to the positive regulation of MHC class II biosynthetic process, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CIITA | Master transcriptional activator of MHC class II genes | Key regulator; mutations cause bare lymphocyte syndrome |
| RFX5 | Part of RFX complex binding MHC class II promoters | Defects lead to MHC class II deficiency |
| RFXAP | Part of RFX complex | Required for CIITA recruitment |
| RFXANK | Part of RFX complex | Mutations cause bare lymphocyte syndrome |
| NFYA | Binds CCAAT box in MHC class II promoters | Enhanceosome component |
| NFYB | Binds CCAAT box | Enhanceosome component |
| NFYC | Binds CCAAT box | Enhanceosome component |
| CREB1 | Binds cAMP response element in MHC class II promoters | Enhanceosome component |
| HLA-DRA | MHC class II alpha chain | Antigen presentation |
| HLA-DRB1 | MHC class II beta chain | Antigen presentation; disease associations |
| CD74 | Invariant chain; chaperone for MHC class II | Required for assembly and trafficking |
| HLA-DM | Peptide exchange catalyst | Facilitates CLIP removal |
| MARCH1 | E3 ubiquitin ligase that downregulates MHC class II | Negative regulator; target for positive regulation |
| JAK2 | Cytokine signaling kinase | IFN-gamma-induced MHC class II expression |
| STAT1 | Transcription factor downstream of IFN-gamma | Induces CIITA and MHC class II |
| IFNGR1 | Interferon gamma receptor | Initiates signaling for MHC class II upregulation |
| CD4 | T cell co-receptor | Binds MHC class II during antigen presentation |
| LAG3 | Inhibitory receptor binding MHC class II | Immune checkpoint |
How Is positive regulation of MHC class II biosynthetic process Regulated?
The positive regulation of MHC class II biosynthetic process is controlled by multiple signaling pathways. The JAK/STAT pathway, activated by IFN-gamma, induces CIITA transcription, which in turn drives MHC class II gene expression. Suppression of the JAK/STAT pathway inhibits neuroinflammation in Parkinson's disease models, highlighting the link between cytokine signaling and MHC class II regulation. Additionally, March-I (MARCH1) ubiquitinates MHC class II molecules, targeting them for degradation, and its downregulation enhances MHC class II surface expression. Other regulators include the RFX complex, NF-Y, and CREB, which form an enhanceosome on MHC class II promoters.
positive regulation of MHC class II biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CIITA | Bare lymphocyte syndrome; cancer immune evasion | Knockout in antigen-presenting cells |
| HLA-DRA | Autoimmunity; cancer | Point mutation to alter peptide binding |
| MARCH1 | Immunity and disease; autoimmunity | Knockout to stabilize MHC class II |
| JAK2 | Neuroinflammation; Parkinson's disease | Knockout or point mutation in microglia |
| STAT1 | IFN-gamma signaling; cancer | Knockout in tumor cells |
Cancer immune evasion
Loss of MHC class II expression on tumor cells is a mechanism of immune evasion. In BRAF-mutant anaplastic thyroid cancers, loss of tumor cell MHC class II drives MAPK inhibitor insensitivity, suggesting that restoring MHC class II biosynthesis could overcome drug resistance. In human bladder cancer, intratumoral CD4+ T cells mediate anti-tumor cytotoxicity, and this function depends on MHC class II expression. In brain tumors, MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids.
Autoimmunity and neuroinflammation
Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis and show altered MHC class II expression, implicating MHC class II biosynthesis in autoimmune demyelination. In Parkinson's disease models, suppression of the JAK/STAT pathway inhibits neuroinflammation, linking MHC class II regulation to neurodegeneration.
Renal fibrosis
MHC class II in renal tubules plays an essential role in renal fibrosis, suggesting that positive regulation of MHC class II biosynthesis contributes to fibrotic kidney disease.
From positive regulation of MHC class II biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CIITA affect MHC class II biosynthesis? | CIITA knockout cell line |
| Does a point mutation in HLA-DRA alter antigen presentation? | HLA-DRA point-mutation knock-in |
| Does tagging MHC class II with GFP affect trafficking? | Tagged knock-in of HLA-DRA |
| Does overexpression of CIITA increase MHC class II? | CIITA overexpression cell line |
| Does March-I regulate MHC class II surface levels? | MARCH1 knockout or overexpression |
| Does JAK/STAT inhibition reduce MHC class II in neuroinflammation? | JAK2 knockout in microglial cells |
How to Study the positive regulation of MHC class II biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | mRNA levels of MHC class II genes | Transcriptional regulation |
| Flow cytometry | Surface MHC class II protein | Immune cell phenotyping |
| Western blot | Total MHC class II protein | Biosynthesis and stability |
| Confocal microscopy | Subcellular localization | Endosomal trafficking |
| Antigen presentation assay | CD4+ T cell activation | Functional outcome |
| CRISPR knockout | Gene function | Loss-of-function studies |
| Proteomics | Protein interactions | Enhanceosome composition |
Transcriptional profiling
RNA-seq and qPCR can measure mRNA levels of MHC class II genes (HLA-DRA, HLA-DRB1) and regulators such as CIITA, providing a readout of positive regulation at the transcriptional level [1,3].
Protein analysis
Western blotting and flow cytometry using antibodies against MHC class II (e.g., HLA-DR) and invariant chain (CD74) quantify protein levels and surface expression, reflecting biosynthetic output [6,8].
Imaging
Confocal microscopy and live-cell imaging of fluorescently tagged MHC class II molecules reveal endosomal trafficking and assembly dynamics.
Functional assays
Antigen presentation assays using CD4+ T cell hybridomas or proliferation assays measure the functional consequence of altered MHC class II biosynthesis [1,4].
How CRISPR Can Be Used to Study GO:0045348 positive regulation of MHC class II biosynthetic process
Knockout
CRISPR knockout of CIITA, RFX5, or other regulators ablates MHC class II biosynthesis, providing a clean loss-of-function model to study positive regulation [1,3].
Point Mutation
Point mutations in HLA-DRA or HLA-DRB1 can alter peptide-binding specificity or stability, allowing precise dissection of biosynthetic regulation.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) into MHC class II genes enables real-time tracking of biosynthesis and trafficking.
Overexpression
Overexpression of CIITA or IFN-gamma-induced pathways boosts MHC class II biosynthesis, useful for studying enhanced antigen presentation.
How EDITGENE Supports positive regulation of MHC class II biosynthetic process Research
Researchers studying positive regulation of MHC class II biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in MHC class II expression, antigen presentation, or immune evasion. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of MHC class II biosynthetic process research.
Frequently Asked Questions About positive regulation of MHC class II biosynthetic process
What is GO:0045348?
GO:0045348 is the Gene Ontology term for positive regulation of MHC class II biosynthetic process, describing any process that increases the production of MHC class II molecules.
What genes are involved in positive regulation of MHC class II biosynthetic process?
Key genes include CIITA, RFX5, RFXAP, RFXANK, NFYA, NFYB, NFYC, CREB1, HLA-DRA, HLA-DRB1, CD74, and MARCH1 [6,8].
Why is MHC class II biosynthesis important in cancer?
MHC class II expression is required for CD4+ T cell-mediated anti-tumor immunity, and its loss drives immune evasion and drug resistance [1,3].
How is MHC class II biosynthesis regulated?
It is regulated transcriptionally by CIITA and the enhanceosome, and post-translationally by March-I-mediated ubiquitination [6,8].
What diseases are associated with MHC class II dysregulation?
Cancer, multiple sclerosis, Parkinson's disease, and renal fibrosis are linked to altered MHC class II biosynthesis [2,3,5,7].
What methods study MHC class II biosynthesis?
RNA-seq, flow cytometry, Western blot, confocal microscopy, and antigen presentation assays are commonly used [1,6,8].
Can CRISPR be used to study MHC class II regulation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools for dissecting MHC class II biosynthesis [1,3].
What is the role of CIITA in MHC class II biosynthesis?
CIITA is the master transcriptional activator that recruits the enhanceosome to MHC class II promoters.
How does March-I affect MHC class II?
March-I ubiquitinates MHC class II, targeting it for degradation, thus negatively regulating its surface expression.
What is the link between JAK/STAT and MHC class II?
JAK/STAT signaling downstream of IFN-gamma induces CIITA and MHC class II expression; its suppression reduces neuroinflammation.
Conclusion
GO:0045348, positive regulation of MHC class II biosynthetic process, is a fundamental biological process that governs adaptive immunity by controlling the abundance of MHC class II molecules. Its dysregulation is implicated in cancer, autoimmunity, and neurodegeneration, making it a prime target for therapeutic intervention [1,3,5,7]. Understanding the molecular players and regulatory mechanisms provides a foundation for developing novel immunotherapies. EDITGENE offers a comprehensive suite of CRISPR services to study this process, from knockout and point mutation to knock-in and overexpression models, empowering researchers to uncover new insights into MHC class II biology.
References
- 1. Oh DY et al.. 2020. Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.. Cell 181(7):1612-1625.e13 PMID: 32497499
- 2. Falcão AM et al.. 2018. Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis.. Nat Med 24(12):1837-1844 PMID: 30420755
- 3. Tiedje V et al.. 2025. Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.. J Clin Invest 135(20) PMID: 40828595
- 4. Kilian M et al.. 2023. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.. Cancer Cell 41(2):235-251.e9 PMID: 36638785
- 5. Zhou Y et al.. 2021. MHC class II in renal tubules plays an essential role in renal fibrosis.. Cell Mol Immunol 18(11):2530-2540 PMID: 34556823
- 6. Bandola-Simon J et al.. 2023. Regulation of MHC class II and CD86 expression by March-I in immunity and disease.. Curr Opin Immunol 82:102325 PMID: 37075597
- 7. Hong H et al.. 2024. Suppression of the JAK/STAT pathway inhibits neuroinflammation in the line 61-PFF mouse model of Parkinson's disease.. J Neuroinflammation 21(1):216 PMID: 39218899
- 8. Miller J. 1994. Endosomal localization of MHC class II-invariant chain complexes.. Immunol Res 13(4):244-52 PMID: 7616052
